# Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome

> **NCT02262338** · PHASE1 · COMPLETED · sponsor: **ArmaGen, Inc** · enrollment: 6 (actual)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **DRUG:** AGT-182

## Key facts

- **NCT ID:** NCT02262338
- **Lead sponsor:** ArmaGen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-03-27
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262338, "Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02262338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*